lilly oral glp 1 orforglipron GLP-1 phase 3 weight loss trial FDA approves Foundayo, an oral

While microdosing might seem appealing, sticking to prescribed dosages and consulting a healthcare provider before making any adjustments is important

Many patients experience improvement as their body adjusts to the medication, though some require ongoing management strategies

Given the narrative/scoping scope, no protocol registration was performed, and we did not pool effect estimates

In the Phase III REDEFINE 1 trial, CagriSema demonstrated a 22.7% mean weight loss after 68 weeks, surpassing both monotherapies and placebo

Equinox GLP-1 Protocol: Equinox introduced a GLP-1-focused wellness protocol for its members in personal training sessions

The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine